4/29/2013

The European Medicines Agency's Committee for Medicinal Products for Human Use endorsed the approval of Roche Holding and Curis' advanced basal cell carcinoma drug Erivedge as well as Astellas Pharma and Medivation's prostate cancer treatment Xtandi. Genzyme's MAC1, a tissue-engineered treatment for cartilage defects, and Vivus' erectile dysfunction drug Spedra also received approval recommendations from the panel.

Full Story:
Reuters

Related Summaries